Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells

Tumor relapse and drug resistance are major factors that limit the curability of multiple myeloma (MM). New regimens have improved overall MM survival rates, but patients with high-risk features continue to have inferior outcomes. Chromosome 17p13 deletion (del17p) that includes the loss of the TP53...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yu-Tai, Chiu, Ian, Wang, Qiuju, Bustamante, Jorge, Jiang, Wenxuan, Rycaj, Kiera, Yi, Song, Li, Joey, Kowalski-Muegge, Jeanne, Matsui, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368840/
https://www.ncbi.nlm.nih.gov/pubmed/37042949
http://dx.doi.org/10.1182/bloodadvances.2022009387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368840/
https://www.ncbi.nlm.nih.gov/pubmed/37042949
http://dx.doi.org/10.1182/bloodadvances.2022009387

Ejemplares similares